Micron Biomedical

Micron Biomedical is a private, clinical-stage biotech based in Atlanta, GA, founded in 2013. The company is advancing a novel dissolvable microarray platform for the needle-free delivery of vaccines and therapeutics, designed to be painless, thermostable, and suitable for self-administration. With significant non-dilutive grant funding and partnerships with major global health organizations, Micron is progressing multiple programs, including vaccines for rotavirus, measles/rubella, and influenza, into clinical trials. Its technology addresses critical challenges in global health, including cold chain dependence, need for trained personnel, and vaccine hesitancy.

Proprietary dissolvable microarray for needle-free, painless, thermostable transdermal delivery of vaccines and therapeutics, enabling rapid self-administration.

Micron competes in the needle-free delivery space with companies developing jet injectors, nasal sprays, and other microarray patches (e.g., Vaxxas). Its focus on dissolvable, rapid-delivery microarrays and strong thermostability data are differentiators, but it faces competition from both startups and large pharma companies investing in alternative delivery technologies.